Discover
CVKD
Cadrenal Therapeutics, Inc.
3.17
1 x 3.04
1 x 2.98
bid
ask
-
0.17
5.09%
1 @ 04:00 PM
3.13 -0.04 (1.26%)
| Ytd | -53.24% | |
| 1y | -72.84% |
2.91
day range
3.78
2.55
52 week range
14.64
| Open | 3.22 | Prev Close | 3.34 | Low | 2.91 | High | 3.78 | Mkt Cap | 9.76M |
| Vol | 467.57K | Avg Vol | 70.05K | EPS | -5.59 | P/E | N/A | Forward P/E | -3.02 |
| Beta | N/A | Short Ratio | 1.17 | Inst. Own | 4.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-21 | 50-d Avg | 4.69 | 200-d Avg | 8.05 | 1yr Est | 35.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -1.83 | -2.18 | -0.35 | -19.13% |
| 2024-08-07 | 2024-06 | -19.04 | -2.25 | 16.79 | 88.18% |
| 2024-08-07 | 2024-06 | -19.04 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -1.05 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -1.05 | -1.5 | -0.45 | -42.86% |
| 2024-03-11 | 2023-12 | -1.35 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-12-18 | Noble Capital Markets | Upgrade | Outperform | |
| 2023-11-20 | HC Wainwright & Co. | Upgrade | Buy |
Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-10-04 | MURPHY JOHN RAYMOND | Director | 614.79K | Purchase |
| 2024-04-09 | PHAM QUANG X | Chief Executive Officer | 6.28M | Stock Gift |
| 2023-01-23 | SZOT MATTHEW K | Chief Financial Officer | 500.00K | Stock Award(Grant) |
| 2023-01-23 | WILSON GLYNN | Director | 50.00K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Royal Bank of Canada | 25.00 | 356.00 | 0.00% |
| 2024-09-29 | Bank of America Corporation | 5.00 | 71.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 3.22K | 45.86K | 0.19% |
| 2024-10-30 | Fidelity Total Market Index Fund | 1.11K | 15.81K | 0.07% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 923.00 | 13.16K | 0.06% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 60.00 | 855.00 | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 15 | 2024-08-20 |